Abonnement à la biblothèque: Guest
Critical Reviews™ in Immunology

Publication de 6  numéros par an

ISSN Imprimer: 1040-8401

ISSN En ligne: 2162-6472

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) IF: 1.3 To calculate the five year Impact Factor, citations are counted in 2017 to the previous five years and divided by the source items published in the previous five years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) 5-Year IF: 2.6 The Eigenfactor score, developed by Jevin West and Carl Bergstrom at the University of Washington, is a rating of the total importance of a scientific journal. Journals are rated according to the number of incoming citations, with citations from highly ranked journals weighted to make a larger contribution to the eigenfactor than those from poorly ranked journals. Eigenfactor: 0.00079 The Journal Citation Indicator (JCI) is a single measurement of the field-normalized citation impact of journals in the Web of Science Core Collection across disciplines. The key words here are that the metric is normalized and cross-disciplinary. JCI: 0.24 SJR: 0.429 SNIP: 0.287 CiteScore™:: 2.7 H-Index: 81

Indexed in

p53-Based Immunotherapy of Cancer

Volume 18, Numéro 1-2, 1998, pp. 29-35
DOI: 10.1615/CritRevImmunol.v18.i1-2.40
Get accessGet access

RÉSUMÉ

Immunotherapy targeting p53 missense mutations, which occur in nearly half of all human tumors, is limited by several factors, including the constraints of antigen processing and presentation. Due to the accumulation of mutated p53 molecules in tumors expressing p53 mutations, an alternative approach would be to target wild-type sequence, CTL-defined p53 epitopes. Obviously, the possibility of an autoimmune response is a major potential drawback to this therapy. Immunization of BALB/c mice with bone marrow-derived dendritic cells (DC) generated in the presence of GM-CSF/IL-4 and prepulsed with the H-2Kd-binding wild-type p53232-240 peptide has been shown to induce anti-peptide CTL. These effectors were cross-reactive against sarcomas expressing p53 missense mutations outside of the p53232-240 epitope, but not within it. Mitogen-activated splenocytes, which express elevated levels of p53, were not sensitive to these CTL. The p53 peptide-pulsed DC-based vaccine was shown to be effective in inducing tumor rejection in immunization and therapy models in the absence of any observable deleterious effect on naive mice. The murine model has now been extended to include the use of genetically modified DC-based vaccines as well.

CITÉ PAR
  1. Barrett John, Childs Richard, The Benefits of an Alloresponse: Graft-Versus-Tumor, Journal of Hematotherapy & Stem Cell Research, 9, 3, 2000. Crossref

  2. Hoffmann Thomas K., Bier Henning, Whiteside Theresa L., Targeting the immune system: novel therapeutic approaches in squamous cell carcinoma of the head and neck, Cancer Immunology, Immunotherapy, 53, 12, 2004. Crossref

  3. Tewari Mallika, Sahai Shipra, Mishra Raghvendra R., Shukla Sunit K., Shukla Hari S., Dendritic cell therapy in advanced gastric cancer: A promising new hope?, Surgical Oncology, 21, 3, 2012. Crossref

  4. Shibuya Terry Y., Lum Lawrence G., Pawlowski Tomasz, Whiteside Theresa L., Immunology and Immunotherapy of Head and Neck Cancer, in Head and Neck Cancer, 2003. Crossref

  5. Troudi W., Sadkaoui S., Yacoubi Loueslati B., Ben Abdallah M., Ben Ayoub W., Mrad K., Ben Ayed F., Ben Romdhane K., Benammar El Gaaied A., Analyse de la rupture de tolérance vis-à-vis de la p53 dans le cancer du sein en Tunisie, Immuno-analyse & Biologie Spécialisée, 21, 1, 2006. Crossref

  6. Tong Charles C. L., Kao Johnny, Sikora Andrew G., Recognizing and reversing the immunosuppressive tumor microenvironment of head and neck cancer, Immunologic Research, 54, 1-3, 2012. Crossref

  7. Menendez Daniel, Shatz Maria, Resnick Michael A., Interactions between the tumor suppressor p53 and immune responses, Current Opinion in Oncology, 25, 1, 2013. Crossref

  8. Melief Cornelis J.M., Toes RenéE.M., Medema Jan Paul, Van Der Burg Sjoerd H., Ossendorp Ferry, Offringa Rienk, Strategies for immunotherapy of cancer, in Advances in Immunology Volume 75, 75, 2000. Crossref

  9. Cicinnati Vito R., Dworacki Grzegorz, Albers Andreas, Beckebaum Susanne, Tüting Thomas, Kaczmarek Elzbieta, DeLeo Albert B., Impact of p53-based immunization on primary chemically-induced tumors, International Journal of Cancer, 113, 6, 2005. Crossref

  10. Hoffmann T. K., Whiteside T. L., Bier H., Plattenepithelkarzinome des Kopf-Hals-Bereichs, HNO, 53, 3, 2005. Crossref

  11. Schuler P.J., Hoffmann T.K., Gauler T.C., Bergmann C., Brandau S., Lang S., Immuntherapie von Kopf-Hals-Karzinomen, HNO, 61, 7, 2013. Crossref

  12. Hoffmann Thomas K., Schuler Patrick J., Antigen-specific immunotherapy in head and neck cancer, Advances in Cellular and Molecular Otolaryngology, 1, 1, 2013. Crossref

  13. Cicinnati Vito R., Zhang Xia, Yu Zhengya, Ferencik Stanislav, Schmitz Klaus J., Dworacki Grzegorz, Kaczmarek Elzbieta, Oldhafer Karl, Frilling Andrea, Baba Hideo A., Schmid Kurt W., Grosse-Wilde Hans, Broelsch Christoph E., DeLeo Albert B., Gerken Guido, Beckebaum Susanne, Increased frequencies of CD8+ T lymphocytes recognizing wild-type p53-derived epitopes in peripheral blood correlate with presence of epitope loss tumor variants in patients with hepatocellular carcinoma, International Journal of Cancer, 119, 12, 2006. Crossref

  14. Suzuki Kazufumi, Matsubara Hisahiro, Recent Advances in p53 Research and Cancer Treatment, Journal of Biomedicine and Biotechnology, 2011, 2011. Crossref

  15. Chène Patrick, p53 as a drug target in cancer therapy, Expert Opinion on Therapeutic Patents, 11, 6, 2001. Crossref

  16. Stegh Alexander H, Targeting the p53 signaling pathway in cancer therapy – the promises, challenges and perils, Expert Opinion on Therapeutic Targets, 16, 1, 2012. Crossref

  17. Ferriès Estelle, Connan Francine, Pagès Franck, Gaston Jésintha, Hagnéré Anne-Marie, Vieillefond Annick, Thiounn Nicolas, Guillet Jean-Gérard, Choppin Jeannine, Identification of p53 peptides recognized by CD8+ T lymphocytes from patients with bladder cancer, Human Immunology, 62, 8, 2001. Crossref

  18. Björck Pia, Lie Wen-Rong, Woulfe Susan L., Klein Barbara K., Olson Walter, Storkus Walter J., Progenipoietin-generated dendritic cells exhibit anti-tumor efficacy in a therapeutic murine tumor model, International Journal of Cancer, 100, 5, 2002. Crossref

  19. Würtzen Peter A., Claesson Mogens H., A HLA-A2 restricted human CTL line recognizes a novel tumor cell expressed p53 epitope, International Journal of Cancer, 99, 4, 2002. Crossref

  20. Radhakrishnan Vivek, S. Swanson Mark, K. Sinha Uttam, Monoclonal Antibodies as Treatment Modalities in Head and Neck Cancers, AIMS Medical Science, 2, 4, 2015. Crossref

  21. Weinberg Robert A, How TP53 (almost) became an oncogene, Journal of Molecular Cell Biology, 11, 7, 2019. Crossref

  22. Hoffmann Thomas K., Nakano Koji, Elder Elaine M., Dworacki Grzegorz, Finkelstein Sydney D., Appella Ettore, Whiteside Theresa L., DeLeo Albert B., Generation of T Cells Specific for the Wild-Type Sequence p53264–272 Peptide in Cancer Patients: Implications for Immunoselection of Epitope Loss Variants, The Journal of Immunology, 165, 10, 2000. Crossref

  23. Fedoseyeva Eugenia V., Boisgérault Florence, Anosova Natalie G., Wollish Wendy S., Arlotta Paola, Jensen Peter E., Ono Santa J., Benichou Gilles, CD4+T Cell Responses to Self- and Mutated p53 Determinants During Tumorigenesis in Mice, The Journal of Immunology, 164, 11, 2000. Crossref

  24. Hoffmann Thomas K., Loftus Douglas J., Nakano Koji, Maeurer Markus J., Chikamatsu Kazuaki, Appella Ettore, Whiteside Theresa L., DeLeo Albert B., The Ability of Variant Peptides to Reverse the Nonresponsiveness of T Lymphocytes to the Wild-Type Sequence p53264–272 Epitope, The Journal of Immunology, 168, 3, 2002. Crossref

  25. Venuti Aldo, Progress and challenges in the vaccine-based treatment of head and neck cancers, Journal of Experimental & Clinical Cancer Research, 28, 1, 2009. Crossref

  26. Ho Jenny J.L., Kim Young S., Biliopancreatic malignancy: Future prospects for progress, Annals of Oncology, 10, 1999. Crossref

  27. Agupitan Arjelle Decasa, Neeson Paul, Williams Scott, Howitt Jason, Haupt Sue, Haupt Ygal, P53: A Guardian of Immunity Becomes Its Saboteur through Mutation, International Journal of Molecular Sciences, 21, 10, 2020. Crossref

  28. Liu Yun-Cai, Ubiquitin Ligases and the Immune Response, Annual Review of Immunology, 22, 1, 2004. Crossref

  29. Baar Joseph, Clinical Applications of Dendritic Cell Cancer Vaccines, The Oncologist, 4, 2, 1999. Crossref

  30. Zöchbauer-Müller Sabine, Gazdar Adi F., Minna John D., Molecular Pathogenesis of Lung Cancer, Annual Review of Physiology, 64, 1, 2002. Crossref

  31. Murakami Takayoshi, Tokunaga Naoyuki, Waku Toshihiko, Gomi Shinya, Kagawa Shunsuke, Tanaka Noriaki, Fujiwara Toshiyoshi, Antitumor Effect of Intratumoral Administration of Bone Marrow-Derived Dendritic Cells Transduced with Wild-Type p53 Gene, Clinical Cancer Research, 10, 11, 2004. Crossref

  32. Cheok Chit Fang, Verma Chandra S., Baselga José, Lane David P., Translating p53 into the clinic, Nature Reviews Clinical Oncology, 8, 1, 2011. Crossref

  33. Leibowitz Michael S., Nayak Jayakar V., Ferris Robert L., Head and neck cancer immunotherapy: Clinical evaluation, Current Oncology Reports, 10, 2, 2008. Crossref

Prochains articles

Identification of a novel five-gene prognostic model for laryngeal cancer associated with mitophagy using integrated bioinformatics analysis and experimental verification Dong Song, Lun Dong, Mei Wang, Xiaoping Gao Function of steroid receptor coactivators (SRCs) in T cells and cancers: Implications for cancer immunotherapy Wencan Zhang, Xu Cao, Hongmin Wu, Xiancai Zhong, Yun Shi, Zuoming Sun Electroacupuncture Alleviates Ischemic Stroke by Activating the mTOR/SREBP1 Pathway Jiawang Lang, Jianchang Luo, Luodan Wang, Wenbin Xu, Jie Jia, Zhipeng Zhao, Boxu Lang KIAA1429 induces the m6A modification of LINC01106 to enhance the malignancy of lung adenocarcinoma cell via JAK/STAT3 pathway Di Xu, Ziming Wang, Fajiu Li Effect of p-estrogen receptor at serine on its function and breast growth Yuan Liang, Junhui Qin, Tiancheng Ma, Tong Yang, Zhenyu Ke, Ruian Wang Mechanistic Insights into Tanshinone IIA in the Amelioration of Post-Thyroidectomy Hypoparathyroidism Xiaoyu Qian, Lin Li, Liang Chen, Chao Shen, Jian Tang MiRNA let-7d-5p alleviates inflammatory responses by targeting Map3k1 and inactivating ERK/p38 MAPK signaling in microglia Fan Fang, Cheng Chen Role of Natural Killer Cells as Cell-Based Immunotherapy in Oral Tumor Eradication and Differentiation Both In Vivo and In Vitro Kawaljit Kaur, Anahid Jewett The Current and Future States of Natural Killer Cell-Based Immunotherapy in Hepatocellular Carcinoma Tu Nguyen, Po-Chun Chen, Janet Pham, Kawaljit Kaur, Steven Raman, Anahid Jewett, Jason Chiang Phillygenin alleviated arthritis through the inhibition of NLRP3 inflammasome and Ferroptosis by AMPK Jianghui Wang, Shufang Ni, Kai Zheng, Yan Zhao, peihong zhang, Hong Chang The value of systemic immune-inflammation index and T cell subsets in the severity and prognosis of sepsis Hao Zhou Efficacy and Nuances of Precision Molecular Engineering for Hodgkin's Disease to a Gene Therapeutic Approach Muhammad Imran Qadir, Bilal Ahmed, Nadir Hussain Serum interleukin 6 and ferritin levels are the independent risk factors for pneumonia in elderly patients Hao Yuan, Jing Tian, Lu Wen Exploration of diagnostic markers associated with inflammation in chronic kidney disease (CKD) based on WGCNA and machine learning Qianjia Wu, Yang Yang, Chongze Lin Clinical significance of serum CTRP3 level in the prediction of cardiac dysfunction and intestinal mucosal barrier dysfunction in patients with severe acute pancreatitis Qiang Shao, Lin Sun The protective effect and mechanism of mild hypothermia on pig lung injury after cardiopulmonary resuscitation Jinlin Ren, Fangfang Zhu, Dongdong Sang, Mulin Cong, Shujuan Jiang Exploring mechanism of Zilongjin in treating lung adenocarcinoma based on network pharmacology combined with experimental verification Kang Zhang, Xiaoqun Chen Gastric Cancer Immune Subtypes and Prognostic Modeling: Insights from Aging-Related Genes Analysis Jian Shen, Minzhe Li Effects of different doses of dexmedetomidine on the prevention of postoperative sleep disturbance and serum neurotransmitter level in patients under general anesthesia Huifei Lu, Fei He, Ying Huang, Zhongliang Wei Identification of key ubiquitination-related genes and their associated with immune infiltration in osteoarthritis based on mRNA-miRNA network Dalu Yuan, Hailiang Shen, Lina Bai, Menglin Li, Qiujie Ye Diagnostic and Prognostic value of peripheral neutrophil CD64 index in elderly patients with community-acquired pneumonia Yan Li, Jing Zhang, Suhang Wang, Jie Cao Identification of Metabolism-Related Prognostic Biomarkers and Immune Features of Head and Neck Squamous Cell Carcinoma Rongjin Zhou, Junguo Wang Downregulation of miR-503-5p promotes the development of pancreatic cancer via targeting cyclin E2 Fei Li, Ying-pei Ling, Pan Wang, Shi-cheng Gu, Hao Jiang, Jie Zhu
Portail numérique Bibliothèque numérique eBooks Revues Références et comptes rendus Collections Prix et politiques d'abonnement Begell House Contactez-nous Language English 中文 Русский Português German French Spain